INDICATION AND EFFECT:
TauroLock™-U25.000 is approved for instillation in all central venous access systems. TauroLock™-U25.000 remaining in the catheter prevents the formation of a bacterial biofilm. The catheter stays infection-free and works properly at high patency.
The lock solution contains (cyclo)-taurolidine, citrate (4%) and urokinase (25,000 IU). (Cyclo)-taurolidine has a broad antimicrobial activity (incl. MRSA and VRE). Citrate possesses effective anticoagulant properties.
TauroLock™-U25.000 is available in vials (single use): 5 mL (5 ampoules and 5 vials each per box).
TauroLock™-U25.000 complies with the recommendations for the use of antimicrobial lock solutions (see Literature).
Dissolve the vial content (=25000 IU urokinase) with 5 mL TauroLock™. Between the dialysis sessions, instill the clear colourless solution into the saline-rinsed access system. The filling volume of the catheter/port system should be noted in this context. TauroLock™-U25.000 is used to prevent catheter occlusion (prophylaxis).
The use of TauroLock™-U25.000 is contraindicated in patients with confirmed urokinase intolerance and in patients with citrate or (cyclo)-taurolidine hypersensitivity and in patients concurrently taking drugs that have been demonstrated to undergo undesirable interactions with urokinase, citrate or (cyclo)-taurolidine.
Before the next application, the lock solution is to be aspirated with a syringe and then the system is to be rinsed with saline. If the lock solution inadvertently enters the bloodstream, there is no systemic effect of (cyclo-)-taurolidine due to the rapid degradation producing taurine.
TauroLock™-U25.000 must be stored at 15 – 25 °C and should be used up immediately after reconstitution.
TauroLock™-U25.000 must be neither stored nor transported under freezing conditions. Do not freeze.
This information does not supplant the Instructions for use.